Aberdeen Group plc Purchases 551,412 Shares of Dyne Therapeutics, Inc. $DYN

Aberdeen Group plc raised its position in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 99.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,108,145 shares of the company’s stock after acquiring an additional 551,412 shares during the period. Aberdeen Group plc owned about 0.78% of Dyne Therapeutics worth $21,675,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the company. Chung Wu Investment Group LLC bought a new position in Dyne Therapeutics in the third quarter worth $30,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Dyne Therapeutics by 25.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock valued at $70,000 after buying an additional 1,109 shares during the period. Tower Research Capital LLC TRC increased its holdings in Dyne Therapeutics by 275.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock valued at $100,000 after buying an additional 7,697 shares during the period. Prudential Financial Inc. acquired a new position in shares of Dyne Therapeutics in the 2nd quarter valued at $111,000. Finally, Arkadios Wealth Advisors acquired a new position in shares of Dyne Therapeutics in the 3rd quarter valued at $128,000. Institutional investors own 96.68% of the company’s stock.

Insider Transactions at Dyne Therapeutics

In other news, Director Brian S. Posner purchased 3,000 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The shares were acquired at an average price of $15.06 per share, for a total transaction of $45,180.00. Following the completion of the acquisition, the director directly owned 11,500 shares in the company, valued at approximately $173,190. The trade was a 35.29% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 14.14% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Jefferies Financial Group reissued a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, March 9th. Tudor Pickering set a $23.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, December 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Wednesday, January 21st. TD Cowen reissued a “buy” rating on shares of Dyne Therapeutics in a report on Monday, December 8th. Finally, Evercore cut their target price on Dyne Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Monday, December 15th. Three analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Dyne Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $35.14.

Dyne Therapeutics Price Performance

Shares of DYN stock opened at $18.84 on Monday. Dyne Therapeutics, Inc. has a 1 year low of $6.36 and a 1 year high of $25.00. The firm’s 50 day moving average is $17.15 and its 200-day moving average is $17.82. The firm has a market capitalization of $3.11 billion, a price-to-earnings ratio of -5.32 and a beta of 1.29. The company has a current ratio of 22.25, a quick ratio of 22.25 and a debt-to-equity ratio of 0.15.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02). Sell-side analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.